Nitroimidazole antibiotic (topical/vaginal)

Metronidazole (Vaginal)

NidaGel

Dosage form
Tablet
Available strengths
0.75%
Drug class
Nitroimidazole antibiotic (topical/vaginal)
Common brand
NidaGel

Clinical overview. Metronidazole 0.75% vaginal gel (NidaGel) is inserted once daily at bedtime for 5 days to treat bacterial vaginosis, with a recurrent-disease maintenance option of twice-weekly dosing for several months. It is not recommended in the first trimester of pregnancy, and patients should avoid alcohol during treatment.

Indication

Common therapeutic uses

  • Local treatment of bacterial vaginosis in non-pregnant adults, diagnosed by a thin, grey-white discharge with a fishy odor, vaginal pH greater than 4.5, and clue cells on microscopy, or by Gram stain criteria.
  • Not effective against trichomoniasis (which requires an oral, systemically-absorbed regimen) or candidiasis; confirm the diagnosis before treating.

Pregnancy

Risk assessment and monitoring considerations

  • Metronidazole crosses the placenta and enters the fetal circulation. Vaginal metronidazole should not be used in the first trimester of pregnancy.
  • There is limited experience with vaginal metronidazole specifically in later pregnancy; when treatment of bacterial vaginosis is needed for a pregnancy-related indication (such as reducing risk of preterm birth in a high-risk pregnancy), an oral metronidazole regimen is preferred over the vaginal gel.

Breastfeeding

Infant exposure considerations

  • Systemic absorption after vaginal application is low compared with oral metronidazole, but some absorption does occur. Oral metronidazole is excreted into breast milk; if there is concern, a temporary interruption of breastfeeding can be considered, though many sources consider usual doses compatible with breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • No specific dosing adjustment is described for older adults.

Pediatrics

Use in children and adolescents

  • Not indicated for pediatric use; this is a vaginal product formulated and studied in adult women.

Dosage & Administration

Practical dosing and administration

  • Standard regimen: one applicatorful (approximately 5 g) inserted intravaginally once daily at bedtime for 5 consecutive days.
  • Recurrent bacterial vaginosis (4 or more episodes per year): after completing a 10-day daily induction course, continue with 5 g intravaginally twice weekly as maintenance therapy for 4 to 6 months.
  • Insert using the applicator provided; treatment can be given regardless of the timing of menses.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • No specific vaginal overdose syndrome is described given low systemic absorption; accidental oral ingestion of the tube's contents by a child should be treated as a potential exposure — contact Poison Control for guidance.

Common side effects

Frequently reported tolerability concerns

  • Vulvovaginal itching, burning, or irritation.
  • Vaginal discharge (a watery or gel-related discharge distinct from the original bacterial vaginosis discharge).
  • A metallic taste has been reported even with vaginal use, reflecting some systemic absorption.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Peripheral neuropathy (numbness, tingling in the hands or feet) has been reported rarely, more typically with prolonged systemic use, but should prompt discontinuation if it occurs.
  • Severe hypersensitivity reactions, including rash and, rarely, angioedema.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with a history of blood dyscrasias or central nervous system disease, given the (low but nonzero) systemic absorption of metronidazole with vaginal use.

Contraindications

Situations where therapy may be inappropriate

  • Known hypersensitivity to metronidazole, other nitroimidazole derivatives, or any component of the gel (including parabens).
  • First trimester of pregnancy.

Drug interactions

Clinically relevant combinations

  • Alcohol: a disulfiram-like reaction (flushing, headache, nausea, vomiting) is possible even with vaginal use, due to some systemic absorption — avoid alcohol during treatment and for at least 24 hours after finishing.
  • Warfarin and other oral anticoagulants: metronidazole can potentiate anticoagulant effect even at the lower systemic exposure achieved vaginally; monitor INR if used concurrently.

Food interactions

Meal-related administration

  • None specific beyond the alcohol interaction noted above.

Time of administration

Practical scheduling

  • Insert at bedtime to reduce leakage and maximize contact time with the vaginal mucosa overnight.

Storage

Product handling

  • Store between 15°C and 25°C. Do not freeze.

Patient take-away

Key counselling points for a quick closing summary

  • Complete the full course even if symptoms improve early, to reduce the risk of relapse.
  • Avoid alcohol during treatment and for at least 24 hours afterward, since it can cause flushing, nausea, and vomiting even with this vaginal formulation.
  • Contact your pharmacist or prescriber if you notice numbness or tingling in your hands or feet, or if symptoms do not improve.
  • If pregnant or planning pregnancy, tell your prescriber — this product should not be used in the first trimester.

References

Source material and product information

  1. Health Canada Product Monograph — Metronidazole (Vaginal)

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.